Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hepatitis C | 20 | 2024 | 1580 | 4.360 |
Why?
|
Hepatitis C, Chronic | 10 | 2023 | 1018 | 2.910 |
Why?
|
Rwanda | 34 | 2022 | 656 | 2.510 |
Why?
|
Antiviral Agents | 17 | 2024 | 3037 | 2.350 |
Why?
|
Hepacivirus | 14 | 2024 | 1330 | 2.000 |
Why?
|
Hepatitis B virus | 4 | 2023 | 527 | 0.850 |
Why?
|
Developing Countries | 11 | 2024 | 2868 | 0.790 |
Why?
|
Child Mortality | 2 | 2019 | 199 | 0.680 |
Why?
|
Hepatitis, Viral, Human | 1 | 2020 | 141 | 0.680 |
Why?
|
Antiretroviral Therapy, Highly Active | 3 | 2018 | 1894 | 0.670 |
Why?
|
Africa South of the Sahara | 4 | 2023 | 745 | 0.620 |
Why?
|
Uridine Monophosphate | 1 | 2018 | 68 | 0.610 |
Why?
|
Poverty | 9 | 2023 | 2692 | 0.590 |
Why?
|
Fluorenes | 1 | 2018 | 157 | 0.580 |
Why?
|
Pregnancy Complications, Infectious | 4 | 2024 | 2149 | 0.580 |
Why?
|
Delivery of Health Care | 6 | 2022 | 5334 | 0.570 |
Why?
|
Rural Population | 9 | 2023 | 2277 | 0.560 |
Why?
|
Health Services Accessibility | 12 | 2024 | 5430 | 0.560 |
Why?
|
HIV Infections | 13 | 2023 | 17342 | 0.470 |
Why?
|
Infant Mortality | 1 | 2018 | 751 | 0.450 |
Why?
|
Patient Acceptance of Health Care | 4 | 2020 | 3196 | 0.440 |
Why?
|
Benzimidazoles | 1 | 2018 | 858 | 0.430 |
Why?
|
Anti-Retroviral Agents | 3 | 2018 | 1783 | 0.420 |
Why?
|
Hepatitis B | 3 | 2023 | 704 | 0.410 |
Why?
|
Wounds and Injuries | 3 | 2021 | 2492 | 0.410 |
Why?
|
Medicaid | 3 | 2024 | 2814 | 0.400 |
Why?
|
Liver Cirrhosis | 3 | 2023 | 1927 | 0.400 |
Why?
|
Carbamates | 2 | 2022 | 191 | 0.350 |
Why?
|
Viral Load | 7 | 2019 | 3325 | 0.350 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2023 | 2292 | 0.350 |
Why?
|
HIV | 2 | 2018 | 1580 | 0.340 |
Why?
|
Cause of Death | 3 | 2019 | 3683 | 0.340 |
Why?
|
Infectious Disease Transmission, Vertical | 3 | 2024 | 1351 | 0.310 |
Why?
|
Humans | 72 | 2024 | 760740 | 0.300 |
Why?
|
Hospitals, District | 5 | 2024 | 114 | 0.290 |
Why?
|
Liver Neoplasms | 1 | 2023 | 4309 | 0.280 |
Why?
|
Anti-HIV Agents | 3 | 2018 | 4524 | 0.280 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2015 | 2197 | 0.280 |
Why?
|
Autopsy | 3 | 2019 | 1008 | 0.270 |
Why?
|
Cost of Illness | 4 | 2022 | 1937 | 0.270 |
Why?
|
Primary Health Care | 4 | 2020 | 4677 | 0.260 |
Why?
|
Rural Health Services | 4 | 2021 | 384 | 0.260 |
Why?
|
Hepatitis B, Chronic | 2 | 2023 | 410 | 0.250 |
Why?
|
Public Health | 1 | 2017 | 2671 | 0.230 |
Why?
|
Depressive Disorder, Major | 1 | 2021 | 4764 | 0.220 |
Why?
|
Quality Assurance, Health Care | 1 | 2013 | 2164 | 0.220 |
Why?
|
Health Expenditures | 3 | 2021 | 2363 | 0.210 |
Why?
|
Interviews as Topic | 3 | 2019 | 2697 | 0.210 |
Why?
|
Adult | 28 | 2024 | 220995 | 0.210 |
Why?
|
Hospitals, Public | 2 | 2023 | 201 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3088 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3209 | 0.200 |
Why?
|
Genotype | 4 | 2022 | 12977 | 0.200 |
Why?
|
Aminoisobutyric Acids | 1 | 2022 | 39 | 0.200 |
Why?
|
Ethiopia | 2 | 2022 | 460 | 0.200 |
Why?
|
Malawi | 2 | 2020 | 302 | 0.200 |
Why?
|
Postnatal Care | 1 | 2024 | 260 | 0.200 |
Why?
|
Cross Infection | 2 | 2022 | 1422 | 0.190 |
Why?
|
Bangladesh | 2 | 2021 | 732 | 0.190 |
Why?
|
Kenya | 2 | 2021 | 757 | 0.190 |
Why?
|
Pandemics | 2 | 2021 | 8652 | 0.180 |
Why?
|
Female | 32 | 2024 | 392203 | 0.180 |
Why?
|
Health Promotion | 1 | 2013 | 2206 | 0.180 |
Why?
|
Pharmacy | 1 | 2022 | 91 | 0.180 |
Why?
|
Cross-Sectional Studies | 11 | 2024 | 26065 | 0.180 |
Why?
|
Ambulatory Care | 3 | 2024 | 2768 | 0.180 |
Why?
|
Nutrition Disorders | 1 | 2021 | 204 | 0.180 |
Why?
|
Leucine | 1 | 2022 | 548 | 0.180 |
Why?
|
Cyclopropanes | 1 | 2022 | 432 | 0.180 |
Why?
|
Proline | 1 | 2022 | 455 | 0.170 |
Why?
|
Lactams, Macrocyclic | 1 | 2022 | 318 | 0.170 |
Why?
|
Health Policy | 3 | 2024 | 2682 | 0.170 |
Why?
|
Prospective Studies | 7 | 2022 | 54364 | 0.170 |
Why?
|
Senegal | 1 | 2020 | 255 | 0.170 |
Why?
|
Death, Sudden | 1 | 2022 | 301 | 0.170 |
Why?
|
Quinoxalines | 1 | 2022 | 296 | 0.170 |
Why?
|
Delivery of Health Care, Integrated | 2 | 2021 | 940 | 0.170 |
Why?
|
Nepal | 1 | 2020 | 304 | 0.170 |
Why?
|
Colistin | 1 | 2019 | 44 | 0.160 |
Why?
|
Quality Improvement | 2 | 2015 | 3801 | 0.160 |
Why?
|
Crohn Disease | 2 | 2022 | 2279 | 0.160 |
Why?
|
Pneumonia, Ventilator-Associated | 1 | 2022 | 279 | 0.160 |
Why?
|
Hospitals, Rural | 2 | 2020 | 176 | 0.160 |
Why?
|
Drug Resistance, Multiple, Bacterial | 2 | 2021 | 585 | 0.160 |
Why?
|
Haiti | 1 | 2020 | 550 | 0.160 |
Why?
|
Prenatal Care | 2 | 2024 | 1140 | 0.160 |
Why?
|
Africa | 2 | 2023 | 714 | 0.150 |
Why?
|
Seroepidemiologic Studies | 4 | 2023 | 398 | 0.150 |
Why?
|
Klebsiella Infections | 1 | 2019 | 144 | 0.150 |
Why?
|
Infant, Newborn | 7 | 2022 | 26183 | 0.150 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2020 | 393 | 0.150 |
Why?
|
Klebsiella pneumoniae | 1 | 2019 | 249 | 0.140 |
Why?
|
Postpartum Period | 1 | 2024 | 1178 | 0.140 |
Why?
|
Aspartate Aminotransferases | 1 | 2018 | 414 | 0.140 |
Why?
|
Adolescent | 14 | 2022 | 88247 | 0.140 |
Why?
|
Middle Aged | 18 | 2024 | 220603 | 0.140 |
Why?
|
Male | 23 | 2024 | 360402 | 0.140 |
Why?
|
Case Management | 1 | 2018 | 272 | 0.140 |
Why?
|
Surgical Equipment | 1 | 2016 | 57 | 0.130 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2020 | 12143 | 0.130 |
Why?
|
Safe Sex | 1 | 2017 | 144 | 0.130 |
Why?
|
Nutrition Surveys | 1 | 2023 | 1725 | 0.130 |
Why?
|
Urinary Tract Infections | 1 | 2022 | 802 | 0.130 |
Why?
|
Tanzania | 1 | 2020 | 1390 | 0.130 |
Why?
|
Alanine Transaminase | 1 | 2018 | 601 | 0.130 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2018 | 258 | 0.130 |
Why?
|
Treatment Failure | 1 | 2022 | 2635 | 0.130 |
Why?
|
Referral and Consultation | 2 | 2020 | 3599 | 0.130 |
Why?
|
Refugees | 1 | 2023 | 595 | 0.130 |
Why?
|
Thymidine | 1 | 2015 | 297 | 0.130 |
Why?
|
Prevalence | 6 | 2023 | 15702 | 0.130 |
Why?
|
Pregnancy | 6 | 2024 | 29869 | 0.120 |
Why?
|
Health Status Indicators | 1 | 2021 | 970 | 0.120 |
Why?
|
Treatment Outcome | 7 | 2021 | 64572 | 0.120 |
Why?
|
Anti-Infective Agents | 1 | 2022 | 983 | 0.120 |
Why?
|
Community Health Services | 2 | 2018 | 654 | 0.120 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 745 | 0.120 |
Why?
|
India | 4 | 2024 | 2286 | 0.120 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2021 | 697 | 0.120 |
Why?
|
Endemic Diseases | 1 | 2015 | 191 | 0.110 |
Why?
|
World Health Organization | 2 | 2017 | 1321 | 0.110 |
Why?
|
Infant, Low Birth Weight | 1 | 2018 | 869 | 0.110 |
Why?
|
Syphilis | 1 | 2016 | 243 | 0.110 |
Why?
|
Infant, Newborn, Diseases | 1 | 2018 | 589 | 0.110 |
Why?
|
Feasibility Studies | 1 | 2024 | 5239 | 0.110 |
Why?
|
Young Adult | 13 | 2023 | 59191 | 0.110 |
Why?
|
Health Resources | 2 | 2017 | 934 | 0.100 |
Why?
|
Survival | 1 | 2013 | 161 | 0.100 |
Why?
|
Health Services | 1 | 2017 | 751 | 0.100 |
Why?
|
Qualitative Research | 2 | 2020 | 3017 | 0.100 |
Why?
|
Staphylococcal Infections | 1 | 2021 | 1406 | 0.100 |
Why?
|
Hospitals | 2 | 2023 | 3879 | 0.100 |
Why?
|
Sulfonamides | 1 | 2022 | 1977 | 0.100 |
Why?
|
Infant | 7 | 2020 | 36157 | 0.100 |
Why?
|
Food Supply | 1 | 2018 | 539 | 0.100 |
Why?
|
Multilocus Sequence Typing | 2 | 2021 | 100 | 0.090 |
Why?
|
HIV-1 | 2 | 2018 | 6858 | 0.090 |
Why?
|
Colitis, Ulcerative | 1 | 2022 | 1921 | 0.090 |
Why?
|
RNA, Viral | 1 | 2018 | 2838 | 0.090 |
Why?
|
Risk Factors | 8 | 2021 | 74128 | 0.090 |
Why?
|
CD4 Lymphocyte Count | 1 | 2016 | 2567 | 0.090 |
Why?
|
Socioeconomic Factors | 2 | 2021 | 7805 | 0.090 |
Why?
|
Child, Preschool | 5 | 2020 | 42193 | 0.080 |
Why?
|
Social Support | 2 | 2018 | 2174 | 0.080 |
Why?
|
Chronic Disease | 3 | 2023 | 9310 | 0.080 |
Why?
|
Retrospective Studies | 11 | 2023 | 80583 | 0.080 |
Why?
|
Health Services Needs and Demand | 2 | 2016 | 1400 | 0.080 |
Why?
|
Hepatitis C Antibodies | 2 | 2019 | 147 | 0.080 |
Why?
|
Infant, Premature | 1 | 2018 | 2107 | 0.080 |
Why?
|
United States | 4 | 2024 | 72292 | 0.080 |
Why?
|
Hypertension | 3 | 2024 | 8532 | 0.080 |
Why?
|
Sepsis | 1 | 2022 | 2585 | 0.080 |
Why?
|
Medical Oncology | 1 | 2020 | 2317 | 0.080 |
Why?
|
Insurance, Health | 2 | 2017 | 2495 | 0.070 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2022 | 2423 | 0.070 |
Why?
|
Monitoring, Physiologic | 1 | 2015 | 1780 | 0.070 |
Why?
|
Parents | 2 | 2018 | 3563 | 0.070 |
Why?
|
Practice Guidelines as Topic | 1 | 2024 | 7390 | 0.070 |
Why?
|
Mass Screening | 2 | 2019 | 5425 | 0.070 |
Why?
|
Social Class | 1 | 2015 | 1993 | 0.070 |
Why?
|
Registries | 1 | 2022 | 8209 | 0.070 |
Why?
|
Politics | 2 | 2024 | 813 | 0.060 |
Why?
|
Aged | 7 | 2022 | 169092 | 0.060 |
Why?
|
Surgical Procedures, Operative | 1 | 2016 | 1924 | 0.060 |
Why?
|
Medication Adherence | 1 | 2016 | 2175 | 0.060 |
Why?
|
Communication | 1 | 2017 | 3851 | 0.050 |
Why?
|
Quality of Health Care | 2 | 2018 | 4325 | 0.050 |
Why?
|
Klebsiella | 1 | 2022 | 49 | 0.050 |
Why?
|
Sierra Leone | 1 | 2023 | 169 | 0.050 |
Why?
|
Blood Banks | 1 | 2023 | 108 | 0.050 |
Why?
|
Ghana | 1 | 2023 | 315 | 0.050 |
Why?
|
Tunisia | 1 | 2020 | 36 | 0.050 |
Why?
|
Patient Satisfaction | 1 | 2013 | 3451 | 0.050 |
Why?
|
Vital Signs | 1 | 2022 | 144 | 0.050 |
Why?
|
Diabetes Mellitus | 2 | 2020 | 5838 | 0.050 |
Why?
|
Guatemala | 1 | 2021 | 159 | 0.050 |
Why?
|
Egypt | 1 | 2020 | 96 | 0.050 |
Why?
|
Case-Control Studies | 1 | 2018 | 22153 | 0.050 |
Why?
|
Chile | 1 | 2021 | 256 | 0.040 |
Why?
|
Retreatment | 1 | 2022 | 596 | 0.040 |
Why?
|
Disk Diffusion Antimicrobial Tests | 1 | 2019 | 8 | 0.040 |
Why?
|
Logistic Models | 3 | 2019 | 13248 | 0.040 |
Why?
|
Policy Making | 1 | 2023 | 541 | 0.040 |
Why?
|
Bacterial Typing Techniques | 1 | 2019 | 263 | 0.040 |
Why?
|
Quality of Life | 1 | 2020 | 13359 | 0.040 |
Why?
|
Child | 4 | 2022 | 80089 | 0.040 |
Why?
|
Social Control Policies | 1 | 2017 | 9 | 0.040 |
Why?
|
Directly Observed Therapy | 1 | 2018 | 139 | 0.040 |
Why?
|
Electronic Health Records | 1 | 2015 | 4810 | 0.040 |
Why?
|
Multivariate Analysis | 2 | 2019 | 12043 | 0.030 |
Why?
|
Hepatitis B e Antigens | 1 | 2015 | 133 | 0.030 |
Why?
|
Remission Induction | 1 | 2020 | 2391 | 0.030 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2015 | 294 | 0.030 |
Why?
|
Respiratory Tract Diseases | 1 | 2020 | 750 | 0.030 |
Why?
|
Sentinel Surveillance | 1 | 2016 | 291 | 0.030 |
Why?
|
Delayed Diagnosis | 1 | 2018 | 463 | 0.030 |
Why?
|
Population Density | 1 | 2014 | 193 | 0.030 |
Why?
|
Disease Management | 2 | 2015 | 2506 | 0.030 |
Why?
|
Professional-Family Relations | 1 | 2017 | 495 | 0.030 |
Why?
|
RNA | 1 | 2023 | 2713 | 0.030 |
Why?
|
Statistics, Nonparametric | 1 | 2018 | 2851 | 0.030 |
Why?
|
Community Health Centers | 1 | 2016 | 460 | 0.030 |
Why?
|
Medically Uninsured | 1 | 2017 | 835 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2022 | 6305 | 0.020 |
Why?
|
Social Stigma | 1 | 2018 | 769 | 0.020 |
Why?
|
Neoplasms | 1 | 2020 | 22131 | 0.020 |
Why?
|
Sexually Transmitted Diseases | 1 | 2017 | 661 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2018 | 20988 | 0.020 |
Why?
|
Vaccination | 1 | 2023 | 3370 | 0.020 |
Why?
|
Residence Characteristics | 1 | 2018 | 2092 | 0.020 |
Why?
|
Pregnancy Outcome | 1 | 2018 | 2921 | 0.020 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2021 | 3415 | 0.020 |
Why?
|
Heart Failure | 2 | 2021 | 11670 | 0.020 |
Why?
|
Models, Statistical | 1 | 2020 | 5074 | 0.020 |
Why?
|
Medicare | 1 | 2022 | 6774 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2020 | 15829 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2018 | 14599 | 0.010 |
Why?
|
Insulin | 1 | 2015 | 6593 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2015 | 10203 | 0.010 |
Why?
|
Hospitalization | 1 | 2016 | 10708 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2018 | 39062 | 0.010 |
Why?
|
Time Factors | 1 | 2017 | 39908 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2019 | 58919 | 0.010 |
Why?
|